Dapawin Tablet 5 mg

Dapawin Tablet 5 mg Uses, Dosage, Side Effects, Food Interaction and all others data.

Trade Name Dapawin Tablet 5 mg
Generic Dapagliflozin Propanediol
Weight 5 mg
Type Tablet
Therapeutic Class Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Manufacturer Beacon Pharmaceuticals PLC
Available Country Bangladesh
Last Updated: October 19, 2023 at 6:27 am
Dapawin Tablet 5 mg
Dapawin Tablet 5 mg

Uses

Dapagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage

Dapawin Tablet 5 mg dosage

5 mg orally once a day.May increase to 10 mg orally once a day in patients tolerating therapy with 5 mg and requiring additional glycemic control

Side Effects

Renal impairment, Female genital mycotic infections, Urinary tract infection, Increased urination, Male genital mycotic infections, Dyslipidemia, Constipation, Discomfort with urination, Extremity pain, Volume depletion, Hypersensitivity

Precaution

CV disease, history of hypotension, UTI, Children, Elderly. Unknown whether distributed in human breast milk; breastfeeding women should discontinue dapagliflozin or nursing taking into account the importance of the drug to the mother

Interaction

Hypoglycemia may occur with concomitant use with insulin & insulin secretagogues eg sulfonylureas. Decrease in Cmax & AUC with rifampin. Increase in Cmax & AUC with mefenamic acid. Increased thiazide & loop diuretic effects; may increase risk of dehydration & hypotension. Pioglitazone.

Pregnancy & Breastfeeding use

Pregnancy Category-C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Contraindication

Hypersensitivity to dapagliflozin propanediol or to any of the excipients. Moderate to severe renal impairment; end-stage renal disease; active bladder cancer. Pregnancy (2nd & 3rd trimester) & lactation.

Special Warning

Renal Impairment: No dosage adjustment is indicated based on renal function. The efficacy is dependent on renal function. lt is not recommended for use in patients with moderate to severe renal impairment (patients with CrCI <60 mL/min or eGFR <60 mL/min/1.73 m2).

Innovators Monograph

You find simplified version here Dapawin Tablet 5 mg


*** Taking medicines without doctor's advice can cause long-term problems.
Share